Compare Bristol-Myers Squibb Co (BMY) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ProShares Ultra Semiconductors — how do they compare? Bristol-Myers Squibb Co trades at $58.55 (market cap $116.30B), while ProShares Ultra Semiconductors trades at $92.1. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals.
| BMY | USD | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $113.53 |
52-Week Low | $42.60 | $39.58 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
USD stock trades at $89.20, down 8.0% over 24 hours amid broader market volatility. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The company announced a future dividend of $0.14 per share scheduled for June 30, 2026. Recent news highlights include coverage of semiconductor sector performance and earnings reports from various firms, though specific financials for USD are not detailed in available data.
The outlook hinges on execution of business strategy and market conditions. Opportunities include potential dividend returns and sector tailwinds, but risks involve price volatility and competitive pressures. Investors should monitor upcoming financial disclosures for fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
